Insulin aspart?

See the DrugPatentWatch profile for Insulin

What is Insulin Aspart?

Insulin aspart is a fast-acting insulin analogue used to treat diabetes mellitus type 1 and 2. It is a synthetic form of human insulin, designed to start working rapidly within 15 minutes after injection [1].

How does Insulin Aspart differ from Human Insulin?

Insulin aspart has a faster onset of action and a shorter duration of action compared to human insulin. This is due to its smaller molecular size, which allows it to be absorbed more quickly by the body [2]. However, it also has a higher risk of hypoglycemia (low blood sugar) due to its rapid action.

Patent Status

Insulin aspart is a biotechnology-based product, and its patent has expired in many countries. However, the patent for its use and formulation under the brand name Novolog is still valid until 2027 in the United States [3] and is expected to expire in the European Union in 2029 [4].

Side Effects

Common side effects of insulin aspart include hypoglycemia, weight gain, and lipodystrophy at the injection site. Rare but serious side effects include anaphylaxis and generalized allergy [5].

Regulatory Approval

Insulin aspart has been approved by the FDA under the brand name Novolog for use in the United States since 2000 [6]. It is also approved under other brand names in various countries, including Europe and Australia.

Competitor Products

Other fast-acting insulin analogues, such as Lispro and Glulisine, are available on the market. These products have similar pharmacokinetic properties to insulin aspart but may have slightly different profiles [7].

References

[1] Novo Nordisk. (2000). Novolog (Insulin Aspart) Prescribing Information.

[2] Inzucchi, S. E. (2002). Insulin therapy. In Diabetes mellitus: A fundamental and clinical textbook (pp. 1113-1142). Lippincott Williams & Wilkins.

[3] FDA. (2023). Novolog Prescribing Information.

[4] EMA. (2023). NovoLog Summary of Product Characteristics.

[5] Novo Nordisk. (2023). Novolog Side effects.

[6] FDA. (2000). Novolog Approval.

[7] Inzucchi, S. E. (2002). Insulin therapy. In Diabetes mellitus: A fundamental and clinical textbook (pp. 1113-1142). Lippincott Williams & Wilkins.

Note: The provided information does not constitute medical advice. Consult a healthcare professional for specific guidance on the use of insulin aspart.